Skip to main content
OpenTrials

Clinical trial condition

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Explore clinical trials studying Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Study availability and eligibility vary by location and protocol.

22 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trial results

Active, Not Recruiting

Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients

NCT06019676

Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Locations
  • The Royal Marsden Hospital Sutton, Surrey, United Kingdom
  • Buckinghamshire Healthcare NHS Trust Aylesbury, United Kingdom
  • Northern Ireland Cancer Centre, Belfast Health & Social Care Trust Belfast, United Kingdom
  • East Lancashire Hospitals NHS Trust Blackburn, United Kingdom
View Trial Details
Active, Not Recruiting

A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

NCT05676203

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • Ordensklinikum Linz GmbH, Elisabethinen Linz, Austria
  • Krankenhaus der Barmherzigen Brüder Vienna, Austria
  • Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg Heidelberg, Baden-Wurttemberg, Germany
  • Klinikum Wetzlar Wetzlar, Hesse, Germany
View all 43 locations
View Trial Details

Related conditions